La cadena de opciones muestra datos clave de las opciones de acciones de Elicio Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Elicio Therapeutics..

Elicio Therapeutics (NASDAQ:ELTX) Bolsa, Cadena de Opciones

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATPC

BDMD

CGBS

CRKN

DWTX

New Oriental Education & Technology Group

ELTX

EONR

FFWM

GOEV

IROQ

ORKT

RSKD

RYAM

SWKH

TMCI

TPET

TTGT

VATE

Descubre las acciones que lideran el premercado con sorprendentes subidas y caídas. INNOVATE y más protagonistas hoy.

Las acciones de INNOVATE (VATE) cotizan un 19% más alto; 20 acciones que se mueven en el premercado de EE.UU.

ALVO

BBGI

BCAX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Elicio Therapeutics Inc

WIIM

ATXG

ATXG stock has given up its prior gain. Addentax Group shares were trading higher after the company announced it will acquire 8,000 Bitcoins and other cryptocurrencies, including Official Trump.

O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) has outperformed the market over the past 5 years by 12.0% on an annualized basis producing an average annual return of 26.97%. Currently, O'Reilly Automotive has a market capitalization of $77.07 billion. 
Buying $100 In ORLY: If an investor had bought $100 of ORLY stock 5 years ago, it would be worth $329.92 today based on a price of $1352.30 for ORLY at the time of writing.
<h3>O'Reilly Automotive's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747322115_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORLY

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Mizuho analyst Ann Hynes maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $200 to $173.

Price Target

Analyst Ratings

ICLR

Mizuho Maintains Outperform on Icon, Lowers Price Target to $173

Birkenstock Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) shares are trading higher on Thursday after the company reported <a href="https://www.benzinga.com/pressreleases/25/05/ac45431021/birkenstock-reports-strong-fiscal-second-quarter-2025-ahead-of-annual-guidance-raises-fiscal-2025" target="_blank" rel="noreferrer noopener">the second-quarter FY25 results</a>.
Revenue grew&nbsp;19%&nbsp;year over year (Y/Y) on a reported and 18%&nbsp;Y/Y on a constant currency basis to 574&nbsp;million euros. Revenue growth was driven by double-digit unit growth and mid-single-digit growth in Average Selling Price (ASP).
Adjusted EPS stood at 0.55 euro, up 34% Y/Y, in the quarter. In U.S. dollars, revenue of $603.62 million beat the street view of $567.17 million, and adjusted EPS of 58 cents <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">exceeded the consensus of 54 cents</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45326208/birkenstock-has-a-tariff-advantage-going-in-q2-analyst" rel="noreferrer noopener">Birkenstock Has A Tariff Advantage Going In Q2: Analyst</a>
The company witnessed double-digit revenue growth across all segments, including&nbsp;20% Y/Y&nbsp;in the Americas,&nbsp;12%&nbsp;in EMEA, and&nbsp;30%&nbsp;in APAC&nbsp;on a constant currency basis.
DTC and B2B revenue grew&nbsp;17% Y/Y and&nbsp;18% Y/Y,&nbsp;respectively, on a constant currency basis. B2B revenue growth was led by strong Spring/Summer sell-in (sandals/closed-toe), and DTC revenue growth was aided by digital and strong retail.
The gross profit margin reached 57.7%, an increase of 140 basis points from the 56.3% reported in the second quarter of 2024.
This improvement was driven by adjustments to sales prices, better utilization of the new manufacturing capacity that came online in September 2023, and a positive impact from currency translation.
Adjusted EBITDA rose&nbsp;23% Y/Y to 200&nbsp;million euros, with an adjusted EBITDA margin of&nbsp;34.8%, which was up 110&nbsp;basis points Y/Y.
Operating cash outflow rose to 18 million euros in the quarter. As of March 31, 2025, Birkenstock had cash and cash equivalents of 235&nbsp;million euros.
FY25&nbsp;Outlook: The company now expects FY25 revenue&nbsp;growth to be at the upper end of its prior guidance of 15% to 17%&nbsp;in constant currency and raised adjusted EBITDA margin by <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">50 basis points to 31.3% to 31.8%</a>.
Oliver Reichert, CEO and Member of the Board of Directors said, &#8221;We expect that the tariff situation may create a unique shift in consumer behavior in the footwear category with a split between the few brands, like BIRKENSTOCK, who manage strong brand equity through relative scarcity and those who distribute their products with less discipline and pricing integrity. We will navigate these uncertain times from a position of strength.&#8221;
Investors can gain exposure to the stock via Renaissance IPO ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPO#NYSE">IPO</a>).
Price Action: BIRK shares are up 6.04% to $57.78 at the last check on Thursday.
Read Next:&nbsp;&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800974/consumers-go-discount-as-tariff-pressures-mount-warns-analyst" target="_blank" rel="noreferrer noopener">Consumers Go Discount As Tariff Pressures Mount, Warns Analyst</a></li>
</ul>
Image by Josh Forden via Shutterstock

Earnings

Equities

Large Cap

Guidance

BIRK

Birkenstock CEO Is Confident Tariffs Is Not A Disadvantage For The Brand

Cantor Fitzgerald analyst Jonathan Ruykhaver maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Overweight and raises the price target from $85 to $95.

RBRK

Cantor Fitzgerald Maintains Overweight on Rubrik, Raises Price Target to $95

ARAI

Arrive AI Shares Halted On Circuit Breaker To The Downside At $28.80/Share

Shares of Chinese e-commerce giant PDD Holdings Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) fell 2.9% to $115.40 on Thursday, mirroring weakness in Alibaba Group&#8217;s stock, which dropped 7.2% to $124.37 after <a href="https://www.benzinga.com/news/earnings/25/05/45437447/alibaba-stock-slides-5-after-revenue-miss-cloud-spend-hits-free-cash-flow">reporting</a> fourth-quarter results.
What To Know: Despite reporting adjusted earnings per ADS of $1.73—beating analyst expectations of $1.48—Alibaba&#8217;s quarterly revenue of $32.58 billion came in below the $33.08 billion consensus estimate. 
The <a href="https://www.benzinga.com/news/earnings/25/05/45437447/alibaba-stock-slides-5-after-revenue-miss-cloud-spend-hits-free-cash-flow">top-line miss</a> overshadowed solid year-over-year growth in several segments, including a 22% increase in international digital commerce revenue and an 18% rise in cloud services.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a>
Investors appeared concerned by <a href="https://www.benzinga.com/pressreleases/25/05/b45430814/alibaba-group-announces-march-quarter-2025-and-fiscal-year-2025-results">slowing growth</a> in core commerce and a 12% year-over-year decline in logistics unit Cainiao, which is undergoing restructuring. Moreover, a 76% drop in free cash flow, despite a healthy cash position of over $82 billion, raised questions about Alibaba's capital efficiency.
Why It Matters: With Alibaba often viewed as a bellwether for China's consumer and tech sectors, its weaker-than-expected results and market reaction weighed on PDD stock. The selloff also reflects broader investor caution around China's e-commerce outlook on Thursday.
Read Also: <a href="https://www.benzinga.com/25/05/45436747/coreweave-stock-is-volatile-thursday-whats-going-on">CoreWeave Stock Is Volatile Thursday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy PDD Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in PDD Holdings&#8217; case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PDD has a 52-week high of $164.69 and a 52-week low of $87.11.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD Stock Slips Following Alibaba Earnings: What's Going On?

Mizuho analyst Ann Hynes maintains IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Outperform and lowers the price target from $210 to $190.

Mizuho Maintains Outperform on IQVIA Hldgs, Lowers Price Target to $190

Mizuho analyst Gregg Moskowitz maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Neutral and raises the price target from $220 to $250.

Mizuho Maintains Neutral on Zscaler, Raises Price Target to $250

<a href="https://www.semiaccurate.com/2025/05/15/arm-to-launch-their-own-branded-server-cpu/" title="https://www.semiaccurate.com/2025/05/15/arm-to-launch-their-own-branded-server-cpu/">https://www.semiaccurate.com/2025/05/15/arm-to-launch-their-own-branded-server-cpu/</a>

'ARM To Launch Their Own Branded Server CPU' - SemiAccurate

Mizuho analyst Gregg Moskowitz maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $190 to $205.

SNOW

Mizuho Maintains Outperform on Snowflake, Raises Price Target to $205

Zelman &amp; Assoc initiates coverage on Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Underperform rating.

Initiation

Zelman & Assoc Initiates Coverage On Williams-Sonoma with Underperform Rating

Mizuho analyst Gregg Moskowitz maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Outperform and lowers the price target from $425 to $380.

Mizuho Maintains Outperform on Salesforce, Lowers Price Target to $380

MAIA Biotechnology, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NYSE">MAIA</a>), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3, 2025, in Chicago, Illinois. The poster is scheduled for presentation on May 31, 2025, from 01:30pm to 04:30pm CDT in the Lung Cancer track.

Biotech

General

MAIA

MAIA Biotechnology Announces That An Abstract About The Efficacy Data From The Phase 2 THIO-101 Clinical Trial Was Accepted For Poster Presentation At The 2025 Annual Meeting Of The ASCO, Taking Place May 30 To June 3, 2025

Zelman &amp; Assoc initiates coverage on Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with a Outperform rating.

Zelman & Assoc Initiates Coverage On Wayfair with Outperform Rating

TURO

UBER

Turo And Uber Partner To Offer Turo Vehicle Rentals Directly Through The Uber App In The U.S

Mizuho analyst Gregg Moskowitz maintains SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Neutral and lowers the price target from $25 to $24.

SAIL

Mizuho Maintains Neutral on SailPoint, Lowers Price Target to $24

Arrive AI Shares Resume Trade Then Again Halted On Circuit Breaker At $31.05/Share

Mizuho analyst Gregg Moskowitz maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Outperform and raises the price target from $127 to $135.

OKTA

Mizuho Maintains Outperform on Okta, Raises Price Target to $135

Mizuho analyst Gabriel Moreen maintains UGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGI#NYSE">UGI</a>) with a Outperform and raises the price target from $38 to $39.

Mizuho Maintains Outperform on UGI, Raises Price Target to $39

Health Care

Press Releases

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Financing

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Management

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Coherus BioSciences

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Immunic

Inozyme Pharma

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lexeo Therapeutics

OncoCyte

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Senti Biosciences

Instil Bio

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Comments

Elicio Therapeutics

Elicio Therapeutics (ELTX) Opciones

Elicio Therapeutics (NASDAQ:ELTX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL